Indication 
Type 
Form 
Target 
Clinical progress 
Estimated launch time Product Introduction
BGM0504 is patent molecular an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management.
R&D Development
BGM0504: A Dual Agonist in Clinical Phase Ⅱ
Molecule Design: Novel dual agonist with global patent protection
GLP-1R Agonist,confirmed clinical benefits in
● Glycemic control
● Reduced body weight
● Improvement in several cardiovascular risk factors
GIPR agonist, potential benefits in
● Multiple pathways to enhance the efficacy of GLP-1R agonist
● Blocked emesis and attenuates illness-like behaviors elicited by GLP-1R activation.
Pre-clinical Data: Compared to Tirzepatide
Directly compete with Tirzepatide
● CAMP accumulation assay showed that the potency of BGM0504 is approximately 2-fold higher than tirzepatide.
● Demonstrated better efficacy and safety in animal study than tirzepatide. NOAEL values for repeated toxicity were higher than tirzepatide reported.
Clinical Progress: Phase Ⅲ study
● BGM0504 shows superior PK profile compared to tirzepatide in health volunteers with higher exposure.
● BGM0504 shows greater body weight reductions at same close comparing to tirzepatide.
● Finished Phase
● Finished Pharse Ⅱ study and expected to be in Pharse Ⅲ in August 2024.
Project Cooperation
Technology First
We offer a variety of transmission components
Product License-out
● Biosimilar polypeptide molecules
● Patent formulation tech-package.
● Liscense-out at early/late clinical stage.
Technique License-out
● Client's polypeptide
● Type 1 original drug
● Milestone fee.
Certificate Display
Exhibition Photos
Company Profile
Hot Tags: bgm0504 injection glp-1/gip receptor agonist, China bgm0504 injection glp-1/gip receptor agonist manufacturers, suppliers, 4-Phenetidine, 910463 68 2 Weight Loss, anti-arthritis, 1093861-60-9, 439685-79-7, infants nutrition
